In the early 1990s, two independent studies noted the presence of specific KRAS proto‐oncogene GTPase (KRAS) and NRAS proto‐oncogene GTPase (NRAS) mutations in cfDNA from pancreatic adenocarcinoma [22] and patients with acute myelogenous leukemia [22, 23]. This evidence concerns the gene KRAS and acute myeloid leukemia.